13054-02-9

Basic information

• Product Name: 6-Iodopyridine-3-carboxylic acid
• Synonyms: 6-Iodopyridine-3-carboxylic acid
• CAS NO: 13054-02-9
• Molecular Formula: C₆H₄INO₂
• Molecular Weight: 249.00593
• Mol File: 13054-02-9.mol

Chemical Properties

• Melting Point: 189-190 °C(Solv: water (7732-18-5))
• Boiling Point: 355.2±27.0 °C(Predicted)
• Appearance: /
• Density: 2.123±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 3.29±0.10(Predicted)
• CAS DataBase Reference: 6-Iodopyridine-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Iodopyridine-3-carboxylic acid(13054-02-9)
• EPA Substance Registry System: 6-Iodopyridine-3-carboxylic acid(13054-02-9)

Safety Data

• Hazardous Substances Data: 13054-02-9(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
6-Iodopyridine-3-carboxylic acid serves as a versatile building block in organic synthesis, enabling the preparation of a variety of other compounds. Its reactivity and functional group compatibility make it a valuable intermediate for creating complex organic molecules.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 6-Iodopyridine-3-carboxylic acid is utilized for the development of pharmaceuticals. Its structural features allow for the design and synthesis of potential drug candidates, contributing to the discovery of new therapeutic agents.
Used in Pharmaceutical Development:
6-Iodopyridine-3-carboxylic acid plays a crucial role in the pharmaceutical industry, where it is employed in the synthesis of active pharmaceutical ingredients. Its unique properties facilitate the creation of novel drugs with improved efficacy and selectivity.
Used in Agrochemicals:
6-Iodopyridine-3-carboxylic acid also finds application in the development of agrochemicals, where it can be used to synthesize new pesticides or herbicides. Its chemical structure allows for the design of molecules with targeted biological activity against pests or weeds.
Used in Material Science:
6-Iodopyridine-3-carboxylic acid has potential applications in material science due to its unique chemical properties. It can be incorporated into the design of new materials with specific characteristics, such as conductivity, magnetism, or optical properties.
Used in Catalysis:
The presence of the iodine atom in 6-Iodopyridine-3-carboxylic acid makes it a candidate for use in catalysis. It can act as a catalyst or be used in the development of catalytic systems for various chemical reactions, enhancing reaction rates and selectivity.
Used in Biological Studies:
The iodine atom in 6-Iodopyridine-3-carboxylic acid allows for the synthesis of radio-labeled compounds, which are useful in biological studies. These radio-labeled compounds can be employed to track biological processes or to study the mechanisms of action of drugs and other molecules in living organisms.

Upstream product

• 5326-23-8 6-Chloro-3-pyridinecarboxylic acid 
• 10034-85-2 hydrogen iodide 
• 38496-18-3 2,6-dichloropyridine-3-carboxylic acid 

Downstream Products

• 893397-44-9 BMS-688521 
• 1233246-23-5 C₂₂H₁₈Cl₂N₄O₃ 
• 1204535-97-6 4-({(3S)-4-[(6-iodo-3-pyridinyl)carbonyl]-3-methyl-1-piperazinyl}sulfonyl)-3-methylbenzonitrile 
• 59-67-6 nicotinic acid 
• 151917-39-4 ethyl 6-iodonicotinate 
• 173157-33-0 methyl 6-iodo-3-pyridinecarboxylate 

Relevant articles and documents

A new and efficient synthesis of 6-[(5 S,9 R)-9-(4-Cyanophenyl)-3-(3,5- dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl]nicotinic acid, a potent LFA-1/ICAM inhibitor

An efficient synthesis of 6-[(5S,9R)-9-(4-cyanophenyl)-3-(3,5- dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl]nicotinic acid 1 is described. This new process involves an in situ protection of 6-chloronicotinic acid as trimethylsilyl est

N-ALKYL PYRROLES AS HMG-COA REDUCTASE INHIBITORS

HMGCo-A reductase inhibitor compounds useful as hypocholesterolemic and hypolipidemic compounds are provided. Also provided are pharmaceutical compositions of the compounds. Methods of making and methods of using the compounds are also provided. Formula (I).

Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity

Compounds of the formula where R1and R2, independently are alkyl groups having 2 to 8 carbons; R3is hydrogen or lower alkyl; X is S, O or N—R4where R4is hydrogen or lower alkyl; Y is phenyl or pyridyl

Method for inhibiting gene expression promoted by AP1 protein with RAR beta selective retinoids and method for treatment of diseases and conditions with such retinoids

Retinoid compounds which repress expression of the gene promoted by AP1 protein but which do not significantly activate expression of the genes having RA-responsive elements in their promoter region through RAR alpha and RAR GAMMA receptor subtypes, are u

Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities

Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity. These assays are based on the ability of negative hormones to down-regulate the activity of chimeric retinoid receptors engineered to possess a constitutive transcription activator domain.

SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES

2,2-Dialkyl-4-aryl-substituted benzopyran and benzothiopyran derivatives of the formula STR1 where the symbols have the meaning described in the specification, have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists.

[(3""-thioxacyclohex-1""-enyl)]-but-3'-ene-1'-ynyl]aryl and [(3""-thioxacyclohex-1""-enyl)]-but-3'-ene-1'-ynyl]heteroaryl carboxylic acids and esters having retinoid-like biological activity

Compounds of the formula STR1 where R 1, R 2, R 3, and R 4 independently are H or lower alkyl of 1 to 10 carbons; R 5 is lower alkyl of 1 to 10 carbons, fluoro, chloro, bromo, iodo, nitro, or fluoroalkyl having 1 to 10 carbons; m is an integer having the

Sulfides, sulfoxides and sulfones disubstituted with a tetrahydronaphthalenyl, chromanyl, thiochromanyl or tetrahydroquinolinyl and substituted phenyl or heteroaryl group, having retinoid-like biological activity

STR1 wherein the symbols have the meaning described in the specification, are selective agonists of RXR retinoid receptors.

Acetylenes disubstituted with a 5-amino or substituted 5-amino substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity

Compounds of the formula STR1 having retinoid like biological activity.

Acetylenes disubstituted with 2-tetrahydropyranoxyaryl and aryl or heteroaryl groups having retinoid-like biological activity

Compounds of the formula STR1 wherein R1 -R5, X, Y, A, B are as defined in the specification have retinoid-like biological activity.